Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

28.45 -0.22 (-0.77%)
Streaming Delayed Price Updated: 10:17 AM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
News headline image
2 Reasons to Watch PFE and 1 to Stay Cautious
Pfizer currently trades at $25.89 per share and has shown little upside over the past six months, posting a middling return of 2.7%. The stock also fell shor... 
Via StockStory
Topics Supply Chain
News headline image
The Most Undervalued Healthcare Stock in the S&P 500 Right Now ↗
The market appears to be short-sighted. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
2 Profitable Stocks Worth Your Attention and 1 We Find Risky
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
Topics Energy
News headline image
Pfizer Expands Pneumococcal Vaccine Push With New Programs ↗
Pfizer reports Phase 2 infant vaccine data showing a stronger immune response against serotype 3 versus Prevnar 20. 
Via Benzinga
News headline image
How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise ↗
The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study. 
Via Investor's Business Daily
Topics Stocks
News headline image
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
From Pfizer Inc.
Via Business Wire
News headline image
3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now ↗
These stocks could look like steals in a few years. 
Via The Motley Fool
Topics Intellectual Property
News headline image
CK Life Sciences’ Sequencio Therapeutics Appoints Emily Tan as Chief Operating Officer
HONG KONG SAR - Media OutReach Newswire - 18 May 2026 - Sequencio Therapeutics, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CK Life... 
Via MediaOutReach
News headline image
Up 231%, Is RTX Proving Why It Was a Mistake for Honeywell to Replace RTX in the Dow Jones Industrial Average? ↗
Honeywell was added to the Dow for its tech focus and diversification across different end markets. 
Via The Motley Fool
Topics Economy Stocks
News headline image
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM ↗
BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a... 
Via MarketBeat
News headline image
Buy, Sell, or Hold Novo Nordisk at $46? ↗
Can Novo Nordisk thrive under intense competitive pressures? 
Via The Motley Fool
News headline image
My Top 3 Healthcare Stocks for May 2026 ↗
Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries. 
Via The Motley Fool
News headline image
2 Ways to Play the Big Pharma Patent Cliff ↗
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize. 
Via MarketBeat
Topics ETFs Intellectual Property
News headline image
1 Stock Under $50 to Target This Week and 2 We Avoid
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
Via StockStory
News headline image
Pfizer Just Locked In Its Next 5 Years of Growth -- Here's How ↗
The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and money to work on other profit centers. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗
Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market. 
Via The Motley Fool
News headline image
Valneva Q1 Earnings Call Highlights ↗
Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme... 
Via MarketBeat
Topics Earnings
News headline image
These Analysts Increase Their Forecasts On Arvinas After Q1 Results ↗
Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for... 
Via Benzinga
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Investors can find much better opportunities. 
Via The Motley Fool
News headline image
3 Struggling Stocks That Could Make for Great Contrarian Buys ↗
These stocks are facing some headwinds, but they may prove to be big winners in the long run. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
From Pfizer Inc.
Via Business Wire
News headline image
The Top 5 Analyst Questions From Novavax’s Q1 Earnings Call
Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant positive market reaction. Manag... 
Via StockStory
Topics Earnings
News headline image
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer ↗
Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval. 
Via Benzinga
News headline image
Prediction: Pfizer Will Beat the Market Over the Next 5 Years ↗
It's a great time to "buy low." 
Via The Motley Fool
Topics Intellectual Property
News headline image
Up 373%, Is ExxonMobil Proving Why It Was a Mistake for Salesforce to Replace ExxonMobil in the Dow Jones Industrial Average? ↗
The Dow Jones Industrial Average would be even higher if it had more exposure to energy stocks. 
Via The Motley Fool
Topics Stocks
News headline image
Arvinas Q1 Earnings Call Highlights ↗
Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline... 
Via MarketBeat
Topics Earnings
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Next-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
From Arvinas Inc.
Via GlobeNewswire
News headline image
Is Pfizer a Buy, Sell, or Hold in 2026? ↗
Can a push into oncology and next-generation therapies make up for Pfizer's post-Covid letdown? 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.